儿童重复全脊柱随访成像的累积有效剂量与癌症风险:EOS微剂量方案究竟有多微
该研究用蒙特卡洛软件PCXMC模拟EOS微剂量方案全脊柱成像的器官吸收剂量,按ICRP-103计算5至18岁脊柱侧凸患儿的有效剂量与终生归因风险(LAR),并推算美国与香港人群随访期累积剂量与癌症风险;微剂量方案全脊柱正侧位有效剂量为2.54–14.75 μSv,LAR为0.04×10⁻⁶至0.84×10⁻⁶;女孩在相同微剂量方案与随访安排下累积癌症风险统计学显著高于男孩。
要点
- EOS微剂量方案全脊柱正侧位有效剂量为2.54–14.75 μSv。
- 美国与香港人群LAR范围为0.04×10⁻⁶至0.84×10⁻⁶。
- 相同方案与随访下女孩累积癌症风险统计学显著高于男孩。
核心结论
- 通过计算机模拟与解析公式可获得美国与香港人群任何暴露年龄的累积有效剂量与癌症风险;相同微剂量全脊柱成像方案与随访安排下女孩累积癌症风险统计学显著高于男孩。
研究设计与样本
- 采用EOS微剂量方案成像参数输入蒙特卡洛软件PCXMC模拟全脊柱暴露脊柱侧凸患儿的器官吸收剂量,按ICRP-103方法计算性别与年龄特异性有效剂量,并按BEIR VII报告方法估算终生归因风险(LAR)。
诊断标准与关键数值
- 5至18岁患者EOS微剂量方案全脊柱同时后前位与侧位成像的有效剂量为2.54–14.75 μSv。
- 美国与香港人群对应LAR范围为0.04×10⁻⁶至0.84×10⁻⁶。
临床应用与阅片要点
- 可利用该研究结果估算随访期累积有效剂量与癌症风险,并向患者及其父母提供信息。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate and to obtain analytic formulation for the calculation of the effective dose and associated cancer risk using the EOS microdose protocol for scoliotic pediatric patients undergoing full spine imaging at different age of exposure; to demonstrate the microdose protocol capable of delivering lesser radiation dose and hence of further reducing cancer risk induction when compared with the EOS low dose protocol; to obtain cumulative effective dose and cancer risk for both genders scoliotic pediatrics of US and Hong Kong population using the microdose protocol.
METHODS: Organ absorbed doses of full spine exposed scoliotic pediatric patients have been simulated with the use of EOS microdose protocol imaging parameters input to the Monte Carlo software PCXMC. Gender and age specific effective dose has been calculated with the simulated organ absorbed dose using the ICRP-103 approach. The associated radiation induced cancer risk, expressed as lifetime attributable risk (LAR), has been estimated according to the method introduced in the Biological Effects of Ionizing Radiation VII report. Values of LAR have been estimated for scoliotic patients exposed repetitively during their follow up period at different age for US and Hong Kong population.
RESULTS: The effective doses of full spine imaging with simultaneous posteroanterior and lateral projection for patients exposed at the age between 5 and 18 years using the EOS microdose protocol have been calculated within the range of 2.54-14.75 μSv. The corresponding LAR for US and Hong Kong population was ranged between 0.04 × 10-6 and 0.84 × 10-6. Cumulative effective dose and cancer risk during follow-up period can be estimated using the results and are of information to patients and their parents.
CONCLUSION: With the use of computer simulation and analytic formulation, we obtained the cumulative effective dose and cancer risk at any age of exposure for pediatric patients of US and Hong Kong population undergoing repetitive microdose protocol full spine imaging. Girls would be at a statistically significant higher cumulative cancer risk than boys undergoing the same microdose full spine imaging protocol and the same follow-up schedule.
引用
- Law M, Ma WK, Lau D, et al. Cumulative effective dose and cancer risk for pediatric population in repetitive full spine follow-up imaging: How micro dose is the EOS microdose protocol? Eur J Radiol. 2018. PMID: 29571807. doi:10.1016/j.ejrad.2018.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。